Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

US FDA Vs. USP: Regulator Sees Biologic Product Monographs As Barrier To Biosimilars

Apr 02 2018

• By Sue Sutter

boxing gloves isolated on white with american flag stars and stripes

Related Content

Gottlieb Places Drug Pricing Out Front In First Speech To US FDA Staff

May 16 2017

First Three Novel Biologic Suffixes Came Courtesy Of US FDA, Not Sponsors

Jan 27 2018

FDA's Gottlieb Applauds Drug Rebates At Point-Of-Sale

Mar 28 2018

FDA Claims Sole Authority Over Naming Of US-Licensed Biologics

Feb 03 2017

Related Companies

Novartis AG

Amgen, Inc.

Additional Topics

United States Biosimilars Biologics Policy BioPharmaceutical

More from Biosimilars

More from Biosimilars & Generics

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window